Fludase developer NexBio raided, documents seized

Armed and flak-jacketed federal agents descended on vaccine developer NexBio at 8 a.m. yesterday. They escorted employees to parking lots and allowed them to re-enter the building only briefly 40 minutes later. An FBI spokesman wouldn't reveal the type of crime being investigated, but some 20 cardboard boxes were apparently seized. The company is developing Fludase, a powdered inhaler flu treatment. NexBio has received tens of millions of dollars in NIH grants and contracts for the effort. After operating solely with government funding, the company has recently tried to raise money from investors. Story

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.